Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.

Andreas WollenbergT NakaharaC MaariKetty Peris Peter A Lio Matthias Augustin Jonathan Ian SilverbergM J RuedaA M DeLozierE PierceF E YangL SunS BallM TauberC Paul

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)

Baricitinib plus TCS vs. placebo plus TCS showed significant improvements in treatment benefit at Week 16 and rapid significant improvements in HRQoL and impact of AD symptoms on work productivity and functioning through 16 weeks.

Keyphrases

atopic dermatitis
climate change
sleep quality
early onset
high intensity
placebo controlled
physical activity
combination therapy
replacement therapy
phase iii
quantum dots
depressive symptoms
smoking cessation
sensitive detection